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Introduction: Selective tumor targeting strategies based on cell surface molecules enable new personalized diag-
nosis and treatments, potentially lowering adverse effects and increasing efﬁcacy. Radio-immunotargeting gen-
erally relies on a molecule binding to a cancer-speciﬁc target. It is therefore important to understand the
properties of molecular interactions in their working environment and how to translate these properties mea-
sured in vitro into the in vivomolecular imaging situation.
Methods: Time resolved interaction analysis in vitrowas comparedwith a corresponding in vivo xenograft mouse
model. The antibody fragment AbD15179was labeledwith 125I or 111In, and analyzed on cell lines with differing
CD44v6 expression in vitro, and in a dual tumor xenograft model derived from the same cell lines. In vitro
LigandTracermeasurements were analyzedwith TraceDrawer and InteractionMap. Conjugate sensitivity, kinet-
ics, and signal-to-background ratios were assessed for both tumor cells in vitro and xenograft tumors in vivo.
Results: In vitro results revealed a general biphasic appearance of a high- and a low-afﬁnity interaction event. The
111In-labeled fragment displayed the largest proportion of the high-afﬁnity interactionwith increased sensitivity
and retention compared to 125I-Fab. In vivo results were in agreementwith in vitro data,with increased retention,
higher sensitivity and better contrast for the 111In-labeled fragment compared to 125I.
Conclusions: Time resolved binding characteristics measured in vitro largely matched the in vivo performance for
the conjugates, which is promising for future studies. In vitro time-resolved LigandTracer assays are efﬁcient,
rapid, and in this study shown to be able to predict in vivo outcomes.
Advances in Knowledge and Implications for Patient Care: Further studies are needed to conﬁrm these ﬁndings, but
themethod is promising considering the ethical need to reduce the use of laboratory animals, aswell as reducing
costs for the development of tumor targeting compounds in the future.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
There is currently an ongoing paradigm shift in drug discovery and
development, and it is becoming increasingly important to develop
new in vitromodels for studying pharmacokinetics and predicting the
in vivo behavior of drugs [1]. Such methodology, if properly applied
and with data of adequate predictive power, could help to substantially
reduce pain and discomfort as well as reduce the number of animals re-
quired in preclinical research [2]. The challenge is, however, to ensure
that the results obtained by such in vitro methods correlate with the
in vivo situation. Many in vitromodels used today remain poor estima-
tors of in vivo behavior, potentially leading to inaccurate predictions of
in vivo drug interactions [2–5]. This discrepancy may prevent an other-
wise suitable drug candidate from advancing through the development, SE-751 85 Uppsala, Sweden.
elberg).
. This is an open access article underprocess, or allowa less suitable candidate to advance and thuswaste de-
velopment resources.
Radio-immunotargeting generally relies on radiolabeled tracers
binding to speciﬁc target antigens, for example receptors overexpressed
on tumor cells. Not surprisingly, physical interaction characteristics
such as binding strength, retention time and selectivity of target binding
versus background are absolutely critical parameters for the diagnostic
performance. Hence, methods for quantifying and comparing strengths
of molecular interactions are fundamental in the development of new
targeting compounds. Such interactions are highly dependent on the
nature of the environment in which they take place, which inmolecular
imaging applications often are highly complex cell surfaces. Thus, the
choice of interaction assay is restricted by the capability of the assay to
mimic the in vivo situation.
In order to develop safe and effective drugs, it is important to accu-
rately estimate pharmacokinetic parameters as early as possible, and
traditionally the golden standard has been in vivo assays. To mimic the
human environment the vast majority of in vivo pharmacokineticthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cer agents, tumor-xenografts are most commonly used, where human
cancer cells are injected subcutaneously in theﬂankof immunodeﬁcient
nude mice. However, not only animal research is costly and time-
consuming, but it also suffers from inherent species related differences
and strict limitations on sample size due to ethical considerations. Con-
sidering these difﬁculties, it is apparent why reliable in vitromodel sys-
tems that accurately predict the pharmacokinetics of drugs are of
increasing need in cancer research [6,7].
LigandTracer (Ridgeview Instruments AB (RIAB), Vänge, Sweden) is
a novel in vitro method that measures how labeled proteins interact
with target antigens on living cells over time, generating binding traces
that describe kinetic properties of the interaction. This technology and
its validation have previously been described in detail [8,9]. Real-time
interaction data from LigandTracer measurements can be analyzed
with Interaction Map® (RIAB) [10–12]. This mathematical analysis
method translates binding curves to a sum of interactions, each describ-
ing one ligand binding to one target. Results are depicted in a modiﬁed
on–off map and provided as kinetic parameters such as the on-rate (ka),
off-rate (kd) and the afﬁnity (KD), as well as the contribution or weight
of each interaction.
In this paperwe address for theﬁrst time how accurately this in vitro
time-resolved cell binding assay corresponds to outcomes in mouse xe-
nografts when investigating new tracers for tumor targeting. Such
in vitro evaluations can provide an initial characterization of binding
(e.g., on-rate, off-rate, afﬁnity), quality of labeled conjugate
(e.g., occurrence/increase of low-afﬁnity populations), and a chance to
assess interaction differences between standard labeling methods be-
fore moving on to an in vivomodel. Since the binding characterizations
aremade on living cells instead of using ﬁxed antigens on a chip, we be-
lieve that this is closer to an in vivo setting than for example surface
plasmon resonance (SPR) techniques. Furthermore, the characteriza-
tions are made in real-time and not, as many standard radioligand as-
says, by using endpoint methods such as saturation or displacement
binding experiments, where binding is in equilibrium at the time of
measurement [13–15].
The cell surface antigen CD44v6 was used as a cancer-target model,
since it is a non-internalizing antigen commonly overexpressed in sev-
eral cancer types, including head and neck squamous cell carcinoma
(HNSCC) [16,17]. Well performing targeting molecules that bind to
such antigens may be utilized as tools for the challenging tasks of
targeted treatments of small residual disease, and are therefore of
great importance. Early detectionwith a tumor speciﬁcmedical imaging
method such as radio-immunodiagnostics, combining the high sensitiv-
ity and resolution of a PET (positron emission tomography) or SPECT
(single-photon emission computed tomography) camerawith antibody
tumor speciﬁcity, could potentially improve the management of pa-
tients with head and neckmalignancies. The novel CD44v6 targeting re-
combinant Fab-fragment AbD15179 was chosen as a tracer due to its
previously proven performance [18].
Even though interaction analysis of time-resolved binding data ob-
tained with LigandTracer has been used to study several radiotracers
in vitro, no previous study has assessed to what extent this in vitro
assay can be used as a potential predictor of in vivo tumor imaging prop-
erties. If such an assay could reduce the need for animal screening of
multiple lead radiotracers, this could signiﬁcantly facilitate in vitro to
in vivo translation in radio-immunodiagnostics.
Thus, in this study, time resolved interaction analysis in vitro was
compared with results from an in vivo xenograft mouse model.
AbD15179 was labeled with either 125I or 111In, and conjugates from
the same labeling batch were analyzed on two cell lines with differing
CD44v6 expression in vitro, and in a dual tumor xenograft model de-
rived from the same cell lines in vivo. Evaluation of factors such as con-
jugate sensitivity, kinetics, and signal-to-background ratios was then
assessed for both cultured tumor cells in vitro and xenograft tumors
in vivo.2. Materials and methods
2.1. Antibody fragments
The anti-CD44v6 Fab-fragment AbD15179 was supplied from AbD
Serotec. Selection and production of the antibody has been described
previously [19]. The Fab fragment was supplied in 3× PBS and stored
in −80 °C. Fragments for 111In-labeling were ﬁrst separated by size-
exclusion chromatography on a NAP-5 column (Amersham Biosciences,
Uppsala, Sweden) preequilibrated with puriﬁed (MilliQ) water. It was
then freeze-dried and stored at−20 °C before use in order to facilitate
buffer exchange and concentration adjustments.
2.2. Cell lines
The HNSCC human cell line H314 (obtained from European Collec-
tion of Cell Cultures) was cultured in a 1:1 mixture of Ham's F12 and
Dulbecco's modiﬁed Eagle medium (DMEM), supplemented with 10%
fetal calf serum, 2 mM L-glutamine, and antibiotics (100 IU penicillin
and 100 μg/ml streptomycin). H314 has an average antigen density of
approximately 650.000 CD44v6 receptors per cell [10]. The SCC (squa-
mous cell carcinoma) cell line A431 (obtained from American Type Cul-
ture Collection)was cultured in Ham's F10, with the same supplements.
A431 has an average antigen density of approximately 3,000,000
CD44v6 receptors per cell [10].
When used in LigandTracer studies, cells were seeded on a local part
of a 10-cm cell dish (#150350; Nunc) and allowed to adhere ﬁrmly to
the plastics prior to the addition of fresh medium. Experiments were
conducted 2–3 days after seeding.
2.3. Labeling of the Fab fragments
Antibody fragments were labeled with 125I (PerkinElmer, Waltham,
MA, USA) using direct chloramine T labeling [20] (Sigma Aldrich) as de-
scribed previously [19] In brief, a stock solution of 10 MBq 125I was
mixed with 100 μl PBS and 14 μM of the Fab-fragment (140 μl,
0.72 mg/ml in PBS) was added. The reaction was initiated by addition
of 18 mM chloramine T (Sigma Aldrich) in water (40 μl, 4 mg/ml) and
was quenched after 5-min incubation on ice by addition of 21mM sodi-
ummetabisulphite (Merck) inwater (80 μl, 4mg/ml). Each labeled pro-
tein was separated from non-reacted 125I and low-molecular-weight
reaction components on a NAP-5 column pre-equilibrated with PBS.
125I-labeled AbD15179 is referred to as 125I-Fab in this paper.
Labeling of AbD15179 with 111In (Mallinckrodt Medical B.V.) was
done using CHX-A″-DTPA labeling as described previously [10,21]. In
short, to 97 μM AbD15179 solution (15 μl, 5 mg/ml in borate buffer,
pH 9), 4.1 μl of CHX-A″-DTPA solution (1 mg/ml in borate buffer,
0.07 M, pH 9) was added, corresponding to a chelator-to-AbD15179
molar ratio of 5:1. The reaction mixture was incubated overnight at
room temperature, and the conjugated antibody was then separated
from free CHX-A″-DTPA using a NAP-5 column equilibrated with ace-
tate buffer (0.2 M, pH 5.5). Approximately 10 MBq of 111In in acetate
buffer was then added to the conjugated AbD15179, and the reaction
mixture was allowed to incubate for 30 min at room temperature. La-
beled Fab fragment was then separated from non-reacted radionuclide
and low-molecular-weight reaction components by using a NAP-5 col-
umn pre-equilibrated with PBS. 111In-labeled AbD15179 is referred to
as 111In-Fab in this paper.
To determine the purity and stability of the labeled antibody frag-
ments over time, instant thin-layer chromatography (ITLC) was per-
formed on 125I and 111In-labeled conjugates. Samples taken
immediately, as well as stored in PBS at 4 °C, or in serum at 37 °C,
24 h after the labeling procedure was analyzed. Approximately 1 μl of
the conjugate was placed on a chromatography strip (Biodex) and put
into a “running buffer” (70 % acetone or 5 nM citric acid for 125I and
111In respectively), followed by measurements on a Cyclone Storage
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ysis software.
2.4. Real-time binding measurements on SCC cells in vitro
Binding and retention measurements of the radiolabeled conjugates
on H314 and A431 cells were performed in room temperature in vitro
with LigandTracer according to a previously described protocol [10].
No internalization of these conjugates in vitrowas observed in a simul-
taneous study, even after 24 h at 37 °C [18], hence the kinetics for sur-
face receptor binding alone could be detected. Experiments were run
simultaneously to allow the use of the same 125I-Fab and 111In-Fab
batches for both in vitro and in vivo experiments. 125I-Fabwasmeasured
in LigandTracer Grey and 111In-Fab in LigandTracer Yellow. Binding
traces in room temperature using three subsequent concentrations
(10, 30 and 90 nM) of Fab fragments were obtained for at least 1 h per
concentration, followed by a dissociation measurement for at least
13 h. Interaction data were then evaluated using TraceDrawer and In-
teraction Map software. For calculations on conjugate retention, conju-
gate sensitivity and cell to background uptake ratios, data on signal
intensities (counts per second) from each run were exported and
aligned in Microsoft Excel (Microsoft Ofﬁce 2011, Redmond, CA, USA).
For estimations on conjugate retention at selected time points, ﬁve sub-
sequent data points at the chosen times during the dissociation phase
were collected from each measurement, normalized to the start of the
dissociation phase. Conjugate sensitivity was calculated by dividing ob-
tained A431 cell signals (background corrected) with H314 cell signals
for each corresponding time point. Cell to background uptake ratios
were calculated by collecting the last ﬁve data points from each binding
measurement phase (10 nM, 30 nM, 90 nM) where binding was ob-
served to be in equilibrium, and at the end of the dissociation phase (ap-
proximately 13 h after start of dissociation), and dividing the signal
from the cell area to the corresponding background area for each dish.
See section on statistics.
2.5. Biodistribution
Tumor xenografts were formed by injection of A431 and H314 cells
in 20 balb/c (nu/nu) female mice. Themice were housed in a controlled
environment and fed ad libitum. Experiments complied with current
Swedish law and were performed with permission granted by the Upp-
sala Committee of Animal Research Ethics. All mice received two injec-
tions, one in the right posterior leg and one in the left posterior leg.
Twenty mice were injected with 8 × 106 A431 cells, resuspended in
matrigel, in the right posterior leg and 10× 106 H314 cells, resuspended
in complete medium, in the left posterior leg. Three weeks after tumor
cell injection they received an intravenous injection (i.v.) via the tail
vein with 125I-Fab (100 kBq, speciﬁc activity of 20 kBq/μg (28 Ci/
mmol)) and 111In-Fab (100 kBq, speciﬁc activity of 20 kBq/μg (28 Ci/
mmol)), totally 5 μg Fab conjugates in 200 μl PBS (483 nM). At time
points 6 (N=5), 24 (N=5), 48 (N=5) and 72 (N=5) hours the an-
imalswere euthanizedwith amixture of ketamine and xylazin followed
by heart puncture. Tumors and blood were excised, weighed and mea-
sured in a gamma well counter (1480 WIZARD; Wallace Oy). Three in-
jection standards were measured for each group, and background was
measured for 111In. Radioactivity uptake in organs was calculated as
percent of injected activity per gram of tissue (%ID/g). Tumor to organ
ratio was calculated as activity/gtumor divided by activity/gorgan. For as-
sessment of conjugate sensitivity, ratios for A431 tumor uptakewere di-
videdwith H314 tumor uptake in each individual mouse. See section on
statistics.
2.6. Statistical analyses
Kinetic data obtained from LigandTracer studies were analyzed in
TraceDrawer 1.6.1 (Ridgeview Instruments AB, Vänge, Sweden) andusing the Interaction Map kinetic analysis method, as described previ-
ously [11,12,19,22]. Statistical data comparisons were performed using
GraphPad Prism Version 5 (Graphpad Software Inc., La Jolla, CA, USA).
Comparisons of kinetic parameters (high afﬁnity interaction vs low af-
ﬁnity interaction), as well as comparisons between 125I-Fab and 111In-
Fab regarding retention and A431/H314 ratios in vitro and in vivowere
performed using a two-tailed t-test and were considered statistically
signiﬁcant if p b 0.05. Comparisons between several groups (111In-Fab
on A431 vs. 111In-Fab on H314, 125I-Fab on A431, and 125I-Fab on
H314 cells) regarding cells to background (in vitro) or tumor to blood
uptake (in vivo) ratios were performed using one-way ANOVA followed
by Tukey's multiple comparison test, and were considered statistically
signiﬁcant if p b 0.05. Unless otherwise stated, data are presented as
the mean ± standard deviation (SD). N= number of replicates.
3. Results
3.1. Radiolabeling of AbD15179
The labeling yield for 125I-labeling of AbD15179 was 74%, and the
purity of labeled protein was N99.9% according to ITLC analysis. For
AbD15179 111In-labeling the yield and purity were 63% and N96%, re-
spectively. The purity of labeled conjugates stored at 4 °C in PBS, or in
serum at 37 °C, during the experimental period was re-analyzed after
48 h, and was unchanged according to the ITLC analysis.
3.2. In vitro kinetic analysis of labeled conjugates
Real-time in vitromeasurements of conjugate–cell interactionswere
initially evaluated for binding kinetics using TraceDrawer and Interac-
tion Map calculations. An on/off rate plot of the interactions can be
seen in Fig. 1A, and detailed kinetic parameters are displayed in
Fig. 1B. In line with previous studies [10], binding of radiolabeled
AbD15179 to cells mainly consisted of two interactions; one high-
afﬁnity (KD = 11.6 ± 4.96 nM, N = 4) and one low-afﬁnity (KD =
218 ± 94.5 nM, N = 4) binding event (depicted as a red and a black
cluster respectively in Fig. 1A). Both 125I-Fab and 111In-Fab produced
this biphasic binding behavior in both cell lines. The kinetic parameters
ka kd and KD differed signiﬁcantly (p b 0.05) between the high and low
interactions (p b 0.05). Furthermore, in line with previous studies [10]
the proportion of high-afﬁnity binders was considerably higher for
111In-Fab (91% and 93% on H314 and A431 cells respectively) than for
125I-Fab (62% and 63% on H314 and A431 cells respectively) for the
used concentration span (Fig. 1B).
3.3. Dissociation of conjugates in vitro vs. in vivo
The contrast of signal in H314 and A431 cells was assessed for 125I-
and 111In-labeled conjugates both in vitro (LigandTracer) and in vivo
(mouse xenografts). LigandTracer dissociation curves for Fab-fragment
AbD15179 labeled with 125I and 111In in H314 and A431 cells can be
seen in Fig. 2A and B respectively. In vitro, 125I-Fab and 111In-Fab follow
the same pattern in both cell lines, with an initially faster off-rate for
125I-Fab than for 111In-Fab, resulting in a superior retention for 111In-
Fab. For example, one hour after start of dissociation measurements,
90% ± 1.5% (H314 cells) and 94% ± 1.3% (A431 cells) of 111In-Fab
were still retained on the cells, whereas only 74% ± 2.8 % (H314 cells)
and 79% ± 4.3% (A431 cells) of 125I-Fab were retained. Ten hours after
start of dissociation measurements, 70% ± 0.5% (H314 cells) and
79% ± 0.4% (A431 cells) were still retained of 111In-Fab, whereas
51% ± 1.1% (H314 cells) and 61% ± 0.8% (A431 cells) were retained of
125I-Fab. Retention of 111In-Fabwas signiﬁcantly higher than 125I-Fab at
all assessed timepoints (1, 5 and 10 h after dissociation start, p b 0.0001,
N= 5). A similar pattern could be seen in vivo (Fig. 2C and D). 125I-Fab
displayed a more rapid initial dissociation in both investigated tumor
types compared to 111In-Fab, which demonstrated a greater retention
Fig. 1. Kinetics of conjugates binding to CD44v6 on A431 and H314 cells, as measured in vitrowith LigandTracer. Binding of radiolabeled AbD15179 to cells mainly consisted of two inter-
actions; one high-afﬁnity and one low-afﬁnity binding event. (A) Logarithmic on/off rate plot of the association rate constants ka anddissociation rate constants kd of 125I-Fab and 111In-Fab
binding to A431 and H314 cells. Red dots represent high-afﬁnity and black dots correspond to low-afﬁnity binding populations. C1/C2 = 125I-Fab–A431, D1/D2 = 111In-Fab–A431, E1/
E2 = 125I-Fab–H314 and F1/F2 = 111In-Fab–H314 interactions. (B) Results from kinetic ﬁts using the One-To-Two model in TraceDrawer and Interaction Map calculations. Two distinct
binding populations were present for all conjugates; one high-afﬁnity (KD = 11.6 ± 4.96 nM) and one low-afﬁnity (KD = 218 ± 94.5 nM) binding event. 111In-Fab comprised a larger
proportion of high-afﬁnity binders than 125I-Fab as determined by Interaction Map weight calculations.
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points, while 125I-Fab uptake was rapidly reduced with time. At 24 h
post-injection, 90% ± 24% of the 6 h value of 111In-Fab was still present
in H314 tumors, compared to 45% ± 7.5% for 125I-Fab. In A431 tumors,
72% ± 15% and 39% ± 5.8% were retained of 111In-Fab and 125I-Fab re-
spectively. Even 72 h post-injection, 111In-Fab levels were unchanged
in H314 tumors (100% ± 38%) while 125I-Fab had decreased to 28% ±
12%. In A431 tumors, 75% ± 19% of the initial 111In-Fab levels were
retained, compared to only 14% ± 2% of the initial 125I-Fab levels at
72 h post-injection. Retention of 111In-Fab was signiﬁcantly higher
than 125I-Fab at all assessed time points (24, 48 and 72 h p.i., p b 0.05,
N= 5).0
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Differences in conjugate sensitivity of the in vitro and in vivo studies
are shown in Fig. 3, displayed as A431/H314 signal ratios. In vitromea-
surements demonstrated signiﬁcantly higher ratios for 111In-Fab com-
pared to 125I-Fab (p b 0.0001) (Fig. 3A). During binding measurements
using 10 and 30 nMconjugate, 111In-Fab A431/H314 ratioswere around
two, whereas incubation with the highest concentration (90 nM) in-
creased the ratios further, and remained around three throughout the
dissociation measurement. 125I-Fab displayed a ratio around one
throughout the analysis, and it was not possible to distinguish between
A431 and H314 cells at the assessed concentrations. A comparable6
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A431 and H314 tumors were more apparent than for 125I-Fab, with sig-
niﬁcantly higher A431/H314 ratios at 6 h (p = 0.016) and 72 h (p =
0.0016) p.i. (Fig. 3B). The difference in tumor uptake for the 125I-Fab
fragment was diminished at later time points (A431/H314 ratio
0.98 ± 0.10 at 72 h p.i., N= 5), whereas 111In-Fab retained a clear dif-
ference in tumor uptake, ranging between 1.5 and 2 times higher for
the high CD44v6-expressing A431 tumors throughout the study
(A431/H314 ratio 1.5 ± 0.2 at 72 h p.i., N= 5).
Characteristics of in vivo and in vitromeasurements of the 125I-Fab
and 111In-Fabwere also evaluated by calculating the tumor cell to back-
ground ratios in vitro and tumor to blood ratios in vivo. As shown in
Fig. 4, in vitro and in vivomeasurements both demonstrated the highest
ratio for the 111In-Fab A431 model. In vitro, the 111In-Fab A431 model
was signiﬁcantly higher compared to the other models at all assessed
concentrations (p b 0.001) (Fig. 4A). Cell to background ratios were
highest during the dissociation phase (measured approximately 15 h
after start of dissociation), where the low amount of unbound conjugate
present in the incubation medium is expected to generate lower back-
ground. In vivo, the 111In-Fab A431 model demonstrated a signiﬁcantly
higher ratio compared to the other models at 24 h (p b 0.05), 48 h
(p b 0.01) and 72 h (p b 0.05) p.i., with the exception of 125I-Fab in
A431 tumors 24 h p.i., and 111In-Fab in H314 tumors at 72 h p.i.
(Fig. 4B). At 72 h p.i., ratio was 13 ± 3.2 for the 111In-Fab A431 model,A
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4. Discussion
The main purpose of this study was to address whether time re-
solved assays using LigandTracer can complement and possibly replace
some animal studies in pre-clinical development of new tumor
targeting compounds for radio-immunotargeting. To our knowledge,
little has so far been done to systematically validate this in vitromodel
and demonstrate the extent to which it mimics in vivo kinetics.
The possible in vitro–in vivo correlation was investigated by
assessing the kinetics of radiolabeled AbD15179 in two squamous carci-
noma cell lines of different CD44v6 expression. Conjugates from the
same labeling batch were simultaneously characterized both in vitro
with LigandTracer, and in vivo using tumor bearing mice, with tumors
originating from the same cell lines used for in vitro assessment. Simul-
taneous characterization of the same conjugates both in vitro and in vivo
reduced potential bias from, e.g., batch variability, speciﬁc activity or
immunoreactivity. Moreover, by simultaneously injecting the two dif-
ferently labeled tracers into mice carrying double SCC tumors with dif-
ferent CD44v6 expression, biodistribution, tumor uptake, contrast, as
well as speciﬁcity and sensitivity of the tracers could be evaluated
while eliminating inter-subject variability in vivo.time (h)
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vestigated in vitro and in vivo. LigandTracer results demonstrated clear
differences between 125I-Fab and 111In-Fab in vitro, with a slower re-
lease of conjugates for 111In-Fab than for 125I-Fab in both H314 and
A431 cells (Fig. 2). This can be attributed to the considerably larger pop-
ulation of high-afﬁnity binders observed for 111In-Fab than for 125I-Fab
(91%–93% and 62%–63% respectively, see Fig. 1) and as previously
shown to differ signiﬁcantly between 111In-Fab and 125I-Fab [10],
resulting in higher retention of 111In-Fab compared to 125I-Fab on SCC
cells. The larger population of low-afﬁnity 125I-Fab conjugates may be
explained by the relatively harsh conditions of direct 125I-labeling
with chloramine T as shown previously [10]. The slow dissociation of
111In-Fab was also in line with the in vivo data, where the 111In-Fab re-
sulted in a high and stable tumor signal, signiﬁcantly higher compared
to 125I-Fab in both tumor models. However, it cannot be fully excluded
that some of the retention for 111In-Fab seen in vivo could be due to slow
non-receptor mediated internalization of the conjugates by the tumor
cells as the cellular membrane renews itself, trapping this residualizing
radiolabel. In contrast, endocytosis of directly labeled 125I-Fab could
lead to deiodination and excretion of iodotyrosine or free iodine [25].
However, previous in vitro studies have shown that CD44v6 in general
is not an internalizing receptor [23,24], and that AbD15179 in particular
is not internalized into either H314 or A431 tumor cells [18]. Thus, we
hypothesize that the major cause of the initial differences in tumor re-
tention in vivowas due to the larger population of high-afﬁnity binders
for 111In-Fab than for 125I-Fab.
Next, sensitivity of the tracers was compared by assessing the ability
of the conjugates to discern moderately CD44v6-expressing H314 cells
from highly CD44v6-expressing A431 cells. The in vitro and in vivo re-
sults were in agreement, where the 111In labeled Fab fragment showed
signiﬁcant differences in signal intensity between high- and medium
CD44v6-expressing cells and tumors, whereas the 125I-labeled Fab frag-
ment could not sufﬁciently distinguish between the two cell lines at the
concentrations used (Fig. 3). For molecular imaging, this can be an im-
portant parameter for assessment of biomarker density, for tumor char-
acterization, diagnosis, dosing and patient stratiﬁcation, and it is
encouraging that the in vitro results correlated so closely to the in vivo
results.
Furthermore, tumor cell to background in vitro and tumor to blood
ratios in vivo were compared (Fig. 4). Our hypothesis was that the
in vitro situation, where tumor cells are ﬁrst exposed to unbound conju-
gates present in the incubation medium, followed by withdrawal of li-
gand and replacement with medium alone, to some extent resembles
the situation of tumors in vivo, where tumor cells are ﬁrst exposed to
large amounts of unbound conjugates in blood, followed by blood clear-
ance. The in vitro results demonstrated that the highest tumor cell to
background ratio was obtained for 111In-Fab in the A431 model. In
vivo, 111In-Fab again displayed a signiﬁcant tumor delivery advantage
compared to 125I-Fab, with the highest tumor to blood ratio obtained
in the A431 tumors. Even though the in vitromethod does not take fac-
tors such as tumor vascularization, permeability and blood clearance
into account, it is promising that in vitro and in vivo results were in
agreement. However, more studies are needed to further explore to
what extent in vitro tumor cell to background ratios can be used to pre-
dict in vivo tumor to blood ratios.
When evaluating results as awhole, the comparison between in vitro
time-resolved data and the in vivo mouse xenograft model clearly
showed a strong in vitro–in vivo correlation for the assessed parameters.
Due to experimental necessities, measurement times and signal magni-
tudes were different between in vivo and in vitro assays, however the
general shape of the data and performance of each conjugate correlated
strongly. Had the in vivo data not been available, we believe that a rea-
sonable estimation of the comparative tumor targeting performance of
the different labeled conjugates could have been formed based on the
in vitro data alone. It is important to note however, that many aspects
of in vivo experiments simply currently cannot be addressed in cellbased in vitro studies, no matter how complex the model system is.
Today, we are still far away from the pointwhere all necessary informa-
tion required for introducing a new therapeutic drug or imaging agent
into the clinic in terms of safety and efﬁcacy could be gained without
the use of laboratory animals [26]. Moreover, in terms of interactions
on the level of organs and general physiology; in vivo stability of
the conjugate, renal clearance rates, toxicity etc, whole-organism
models remain absolutely essential. However, with a careful choice
of analysis method we can achieve an important informative base
on what will occur in vivo, especially concerning antigen binding ki-
netics; this can enable us to design smaller and yet more informative
animal experiments, and exclude unsuitable conjugates already at
the in vitro level.
With that in mind, we believe that assessment of new binders for
radio-immunotargeting is likely a good candidate for replacing select
animal studies with extended in vitro assays. The performance of a
radiolabeled tracer is dependent on parameters relatively easy to mea-
sure, but generally not on the biological response from the ligand bind-
ing to the target. This is considerably more complicated to examine in
in vitro assays; both because of non-linearities of signaling pathways
and because of the complex tissue and organ-level interactions which
cell assays do not address. In radio-immunodiagnostics, such biological
effects are of less importance if you have a good understanding of the li-
gand interaction parameters (e.g., afﬁnity, Bmax and dissociation), ligand
biodistribution, and tumor speciﬁc parameters such as target expres-
sion levels. This provides a solid base to predict in vivo performance of
the tracer in e.g., SPECT or PET applications.
Through time-resolved binding analysis methods, data can be col-
lected which even go beyond the capability of in vivomodels. Informa-
tion on the total number of binding events and interaction kinetics can
enable the precise ﬁne-tuning of binding characteristics at an early
stage. This can be very important, since changing compound speciﬁcs
and formulation become more complicated the further you reach in
the development pipeline.
To conclude, this study is one of few addressing the problem of
in vitro to in vivo translation in radio-immunodiagnostics. In our case,
time-resolved in vitro experiments could adequately predict in vivo
tumor targeting performance of radiolabeled binders. In some cases
the information from the in vitro assaywas of higher quality and resolu-
tion than the in vivo data, with in-depth kinetic analysis of results. How-
ever, today it is still not feasible to identify an ideal radiotracer based on
the in vitro results alone. We believe that the improvement and devel-
opment of new in vitro techniques and research tools will be critical to
accelerate development of the next generation of tumor targeting diag-
nostic compounds. Furthermore, such a development has the potential
of leading to a reduction in the usage of laboratory animals. Such a re-
duction is naturally of ethical interest, but also essential for reducing
the prohibitively high drug development costs; in turn helping to re-
duce the price, and thereby increasing the availability of modern cancer
treatments.More cost-efﬁcient development of new improved diagnos-
tic and therapeutic tools can only serve to beneﬁt society in general and
cancer patients in particular.Conﬂict of interest
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